BEIJING, Jan. 9, 2014 (GLOBE NEWSWIRE) -- Dehaier Medical Systems Ltd. (Nasdaq:DHRM) ("Dehaier" or the "Company"), an emerging leader in the development, assembly, marketing and sale of medical devices and homecare medical products in China, announced that it has received approval from the Chinese State Food and Drug Administration for its second generation DHR998 Sleep Diagnostic Device. Dehaier has now formed a comprehensive line of products to address the market demands of sleep diagnosis, sleep apnea treatment and CPAP treatment evaluation. This product portfolio should be introduced for sale in early 2014.
Mr. Chen, Dehaier's CEO and President, remarked "our new DHR998 Sleep Diagnostic Device is a technological upgrade based on Dehaier's original high efficiency sleep diagnostic and monitoring product. The new device improves upon its predecessor with an enhanced and more user-friendly operating system and more accurate respiratory analysis across five testing variables: PPG (plethysmograph), oxygen saturation, heart rate, snoring and body position. By using the Morpheus Ox System, the advanced automatic sleep scoring software generates an accurate and reliable sleep study diagnosis, including Apnea Hypopnea Index (AHI), sleep/wake time, and Cheyne-Stokes breathing patterns. The new generation Morpheus Ox is a comprehensive platform that manages a cost-effective sleep services operation, including patient electronic medical records, cardiac and sleep diagnostics outcomes and complete workflow management. The web-based automatic scoring and data management quickly gives users valuable clinical information to improve patient treatment. We will start advertising and selling these products in the first quarter of 2014."
About Dehaier Medical Systems Ltd.
Dehaier is an emerging leader in the development, assembly, marketing and sale of medical products, including respiratory and oxygen homecare medical products. The company develops and assembles its own branded medical devices and homecare medical products from third-party components. The company also distributes products designed and manufactured by other companies, including medical devices from IMD (Italy), Welch Allyn (USA), HEYER (Germany), Timesco (UK), eVent Medical (US) and JMS (Japan). Dehaier's technology is based on six patents, ten software copyrights and proprietary technology. More information may be found at http://www.dehaier.com.cn
This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events, government approvals or performance, and underlying assumptions and other statements that are other than statements of historical facts, including in particular any implications regarding the new DHR998 sleep diagnostic device. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, future developments in payment for and demand for medical equipment and services, implementation of and performance under the joint venture agreement by all parties, and other risks contained in reports filed by the company with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.
CONTACT: Dehaier Medical Systems LimitedSurie Liu
firstname.lastname@example.orgDehaier Medical Systems LimitedTina He
Source: Dehaier Medical Systems Limited